Johnson & Johnson has wrapped up a previously announced pair of transactions, adding one business while divesting another, it said this week.
In the first deal, New Brunswick-based J&J said it has completed the $3.4 billion cash acquisition of Auris Health Inc., a maker of robotic platform technology for diagnostic and therapeutic procedures in the lung. The deal includes an additional $2.35 billion in potential contingent payments if certain milestones are reached.
“The passionate team and differentiated innovation from Auris will help us amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer innovation,” Ashley McEvoy, executive vice president, worldwide chairman, medical devices, for J&J, said in a prepared statement.
The deal was first announced in February.
In the second deal, J&J completed the sale of its Advanced Sterilization Products business, a division of its Ethicon Inc. subsidiary. The $2.8 billion sale of the infection prevention unit to Washington-based Fortive Corp. included $2.7 billion in cash and $0.1 billion of retained net receivables.
That transaction was first announced in June.
